Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Sorbent expands $36M Series B financing

Sorbent Therapeutics, a private biopharmaceutical company developing therapies for cardiovascular and renal disorders, announced today that it has expanded the Company's Series B financing from September 2010 by $36 million.

30 Jun 2011

EHRA, Cardiostim partner to develop common scientific programme committee

EHRA-Europace and Cardiostim, Europe's leading congresses in "electrophysiology" and the treatment of heart rhythm disorders have formed a strategic alliance to ensure the development from year to year of a homogeneous congress programme devised under the direction of a common scientific committee.

30 Jun 2011

ESC Congress 2011 to spotlight 'controversial issues in cardiology'

The scientific programme for this year's ESC Congress, which will take place in Paris from 27-31 August, is now complete and promises to provide journalists with a rich source of front-page news stories and background for topical features.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Modulating interaction between 'rotten eggs' gas and nitric oxide may treat heart failure

Research carried out by scientists from the Peninsula Medical School at the University of Exeter and the National University of Singapore has analysed the complex 'cross talk' between hydrogen sulphide and nitric oxide, both gasses that occur naturally in the body, and found that the interaction may offer potential strategies in the management of heart failure.

30 Jun 2011

LVAD therapy an 'attractive option' for heart failure patients 70 years of age or older

Results of a clinical research study at Sharp Memorial Hospital indicate that patients 70 years of age or older have good functional recovery, survival and quality of life at two years when undergoing left ventricular assist device (LVAD) therapy for heart failure.

29 Jun 2011

Two-pronged 'hybrid' procedure for treatment of atrial fibrillation

Doctors at Washington University School of Medicine in St. Louis are performing a new procedure to treat atrial fibrillation, a common irregular heartbeat.

29 Jun 2011

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.

29 Jun 2011

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.

28 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

Nine-year-old recovers with experimental heart pump

Nine-year-old Greer Underwood was healthy until February 2011. What seemingly began as sinusitis on a Tuesday became almost fatal by the weekend when her heart began to fail. Now, after a historic series of events at the University of Alabama at Birmingham, she's the only child in the country to have used the experimental heart pump, Heartware, as a bridge to transplant.

28 Jun 2011

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

28 Jun 2011

Wildfire exposure may increase risk of heart failure

An EPA study published online Monday in Environmental Health Perspectives finds that the 2008 peat bog wildfires in NC led to an increase in emergency room visits for respiratory and cardiovascular effects.

28 Jun 2011

Diabetes numbers on the rise: Experts worried

According a new international study more than 350 million in the world now have diabetes. The analysis, published online by the Lancet on Saturday, adds several tens of millions to the previous estimate of the number of diabetics and indicates that the disease has become a major global health problem.

27 Jun 2011

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed dosing the first patient in Part B of the ongoing Phase I study.

27 Jun 2011

Redefinition of cardiac hypertrophy term needed

The European Society of Cardiology (ESC) Working Group on Myocardial Function is calling for a redefinition of the term cardiac hypertrophy which is currently used to describe changes to the morphology (structure) of the heart. Instead the position paper, published online today in the European Journal of Heart Failure, suggests that use of the general term myocardial remodelling should be preferred.

27 Jun 2011

New guide indicates when and how genetic testing is useful for inherited cardiac conditions

While genetic inheritance is known to play a role in the multifactorial development of most diseases of the heart, there are also a number of clearly diagnosed cardiac conditions which owe their development to quite specific genetic abnormalities. When these genetic disorders affect the integrity of the heart's muscle they are known as a "cardiomyopathy"; when the disorder affects the heart's "excitability", it is known as a "channelopathy".

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

Anticholinergic medications linked to risk of cognitive impairment, death in older population

A large, long-term study confirms that medications with anticholinergic activity, which include many drugs frequently taken by older adults, cause cognitive impairment. The research is also the first to identify a possible link between these drugs - which include over-the-counter and prescription sleep aids and incontinence treatments - and risk of death.

27 Jun 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.

27 Jun 2011

Heart Failure News and Research

Further Reading

Sorbent expands $36M Series B financing

EHRA, Cardiostim partner to develop common scientific programme committee

ESC Congress 2011 to spotlight 'controversial issues in cardiology'

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Modulating interaction between 'rotten eggs' gas and nitric oxide may treat heart failure

LVAD therapy an 'attractive option' for heart failure patients 70 years of age or older

Two-pronged 'hybrid' procedure for treatment of atrial fibrillation

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Nine-year-old recovers with experimental heart pump

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Wildfire exposure may increase risk of heart failure

Diabetes numbers on the rise: Experts worried

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Redefinition of cardiac hypertrophy term needed

New guide indicates when and how genetic testing is useful for inherited cardiac conditions

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

Anticholinergic medications linked to risk of cognitive impairment, death in older population

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News